Cargando…

Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21

BACKGROUND: The European Medicines Agency (EMA) requires enhanced safety surveillance to be conducted for annual seasonal influenza vaccines with the aim of rapidly detecting any potential new safety concerns before the peak immunisation period of the vaccine in any given year. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Syrkina, Olga, Inamdar, Ajinkya, Wague, Sophie, Monfredo, Céline, Nissilä, Markku, Chabanon, Anne-Laure, Serradell, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358077/ https://www.ncbi.nlm.nih.gov/pubmed/35941631 http://dx.doi.org/10.1186/s12889-022-13898-z

Ejemplares similares

Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season
por: Chabanon, Anne-Laure, et al.
Publicado: (2021)

Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022)

Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season
por: Serradell, Laurence, et al.
Publicado: (2020)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Evaluation of determinants of the serological response to the quadrivalent split‐inactivated influenza vaccine
por: Wu, Shaohuan, et al.
Publicado: (2022)

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
por: Vesikari, Timo, et al.
Publicado: (2019)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea
por: Choi, Won Suk, et al.
Publicado: (2017)

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
por: Liu, Xiaoqiang, et al.
Publicado: (2022)

Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea
por: Lim, Sookyung, et al.
Publicado: (2022)

Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial
por: Robertson, Corwin A., et al.
Publicado: (2019)

Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
por: Chen, Jianmin, et al.
Publicado: (2023)

Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial
por: Ojeda, Joyce, et al.
Publicado: (2019)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16
por: Bricout, Hélène, et al.
Publicado: (2017)

Safety of a quadrivalent influenza vaccine in Vietnamese healthy subjects aged 6 months and older
por: Thiem, Vu Dinh, et al.
Publicado: (2020)

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
por: Nagy, Lisa, et al.
Publicado: (2016)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents
por: Lambert, Stephen B., et al.
Publicado: (2013)

Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
por: Boikos, Constantina, et al.
Publicado: (2021)

Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study
por: Lee, Jin, et al.
Publicado: (2018)

Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial
por: Huang, Xiaoyuan, et al.
Publicado: (2022)

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
por: Thommes, Edward W., et al.
Publicado: (2016)

Safety Profile of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season
por: Salamanca de la Cueva, Ignacio, et al.
Publicado: (2021)

Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea
por: Choe, Sunho, et al.
Publicado: (2023)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production
por: Herrera-Rodriguez, José, et al.
Publicado: (2019)

Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies
por: Verma, Swati, et al.
Publicado: (2017)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial
por: Sesay, Sanie, et al.
Publicado: (2017)

531 Split-virion compared to Subunit Influenza Trivalent Influenza Vaccines Has Greater Effectiveness in Older Adults
por: Talbot, H. Keipp, et al.
Publicado: (2014)

Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand
por: Kittikraisak, Wanitchaya, et al.
Publicado: (2016)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

Effectiveness of the Cell-Derived Inactivated Quadrivalent Influenza Vaccine in Individuals at High Risk of Influenza Complications in the 2018–2019 United States Influenza Season
por: Boikos, Constantina, et al.
Publicado: (2021)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

Native Morphology of Influenza Virions
por: Noda, Takeshi
Publicado: (2012)

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
por: Chen, Yaping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4105kd5psicujqhr8vdm6rb1ft